[go: up one dir, main page]

CL2008003201A1 - Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. - Google Patents

Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.

Info

Publication number
CL2008003201A1
CL2008003201A1 CL2008003201A CL2008003201A CL2008003201A1 CL 2008003201 A1 CL2008003201 A1 CL 2008003201A1 CL 2008003201 A CL2008003201 A CL 2008003201A CL 2008003201 A CL2008003201 A CL 2008003201A CL 2008003201 A1 CL2008003201 A1 CL 2008003201A1
Authority
CL
Chile
Prior art keywords
inhibitors
pat1
gaboxadol
oat
useful
Prior art date
Application number
CL2008003201A
Other languages
English (en)
Inventor
Mie Larsen
Carsten Uhd Nielsen
Birger Brodin Larsen
Rene Holm
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2008003201A1 publication Critical patent/CL2008003201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composición farmacéutica que comprende gaboxadol o una sal del mismo, y uno más inhibidores de pat1 y/o uno o más inhibidores de oat, útil en el tratamiento de trastornos del sueño, entre otros.
CL2008003201A 2007-10-29 2008-10-28 Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. CL2008003201A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701541 2007-10-29
DKPA200801198 2008-09-01
DKPA200801443 2008-10-16

Publications (1)

Publication Number Publication Date
CL2008003201A1 true CL2008003201A1 (es) 2009-10-16

Family

ID=40419047

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003201A CL2008003201A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.

Country Status (5)

Country Link
US (1) US20090143335A1 (es)
AR (1) AR070516A1 (es)
CL (1) CL2008003201A1 (es)
TW (1) TW200924757A (es)
WO (1) WO2009056146A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3151832T (pt) 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3334427A4 (en) * 2015-08-11 2019-02-06 Ovid Therapeutics, Inc. METHOD OF SUSPENSION AND PARENTERAL FORMULATION FOR USE IN INTENSIVE TREATMENT
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
JP2022514275A (ja) * 2018-12-17 2022-02-10 オービッド・セラピューティクス・インコーポレイテッド 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013016A (es) * 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients

Also Published As

Publication number Publication date
WO2009056146A1 (en) 2009-05-07
AR070516A1 (es) 2010-04-14
US20090143335A1 (en) 2009-06-04
TW200924757A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
CO6361917A2 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
EA201200143A1 (ru) Антибактериальная композиция для ротовой полости
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
NI200800261A (es) Tratamientos de alergia ocular
EA201200253A1 (ru) Композиция для лечения муковисцидоза
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ